000 04114nam a22004695i 4500
001 978-1-4419-1513-9
003 DE-He213
005 20140220084506.0
007 cr nn 008mamaa
008 100623s2010 xxu| s |||| 0|eng d
020 _a9781441915139
_9978-1-4419-1513-9
024 7 _a10.1007/978-1-4419-1513-9
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aDittmer, Dirk P.
_eeditor.
245 1 0 _aMolecular Basis for Therapy of AIDS-Defining Cancers
_h[electronic resource] /
_cedited by Dirk P. Dittmer, Susan E. Krown.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2010.
300 _aCCLVI, 200p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aThe Epidemiology of Cancer in People with HIV -- Epidemiology and Clinical Characteristics of Non-AIDS-Defining Malignancies -- HIV-Related Cancer Management in Resource-Limited Settings: A Case Study of Malawi -- Immunology of HIV-Associated Kaposi Sarcoma -- Targeting Signal Transduction Pathways for the Treatment of Kaposi Sarcoma -- Role of NF-?B Inhibitors in HIV-Related Malignancies -- The Molecular Basis of Lytic Induction Therapy in Relation to Gamma herpesvirus (KSHV, EBV)-Associated, AIDS-Related Tumors -- Viral Interleukin-6: Molecular Biology and Pathogenesis -- Targeting the PI3K/Akt/mTOR Pathway in AIDS-Associated Malignancies -- Restoration of p53 Function by MDM2 Inhibition: Potential Strategy to Treat KSHV-Associated Malignancies -- Interferon in Kaposi’s Sarcoma Biology and Therapy -- Metronomic Therapy for HIV-Associated Malignancies -- Targeting EGFR in HPV-Associated Cancer -- Cidofovir Against Human Papillomavirus-Associated Diseases.
520 _aAn increased risk for various cancers is a characteristic of people living with HIV infection. Although only three cancers – Kaposi’s sarcoma, high-grade B-cell lymphomas, and invasive cervical cancer – are considered to be "AIDS-defining" conditions, are associated with oncogenic viruses, and occur with increased frequency as immune function declines, other cancer types also occur significantly more frequently in HIV-positive individuals than in the general population, but are not directly associated with clinical progression to AIDS. Notably these "non-AIDS-defining" cancers include virus-associated cancers such as anal cancer, hepatocellular cancer and Hodgkin’s disease, as well as non-virus associated cancers such as lung cancer. Importantly, there are also large worldwide differences in the incidence and behavior of different AIDS-associated cancers. Although effective combination antiretroviral therapy (cART) may be sufficient in some cases to decrease the incidence or beneficially influence the course of some cancers, in other cases it fails to control cancers in people living with HIV/AIDS. Currently, more than a decade after the widespread introduction of cART, and after major advances in the basic understanding of cancer signaling pathways, we have a unique opportunity to revisit the pathobiology, epidemiology and treatment options for malignancies in people living with HIV/AIDS. Molecular Basis for Therapy of AIDS-Defining Cancers provides a primer on the science of cancer in the setting of HIV infection, as well as examples of novel treatment approaches for HIV-associated neoplasia.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aToxicology.
650 0 _aEmerging infectious diseases.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aPharmacology/Toxicology.
650 2 4 _aInfectious Diseases.
700 1 _aKrown, Susan E.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781441915122
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4419-1513-9
912 _aZDB-2-SBL
999 _c110413
_d110413